Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.

Background: The objective of this study was to assess the utility of the bone formation marker procollagen type 1 amino-terminal propeptide (P1NP) in indicating bone metastases in patients with prostate carcinoma. Alkaline phosphatase (AP) and prostate-specific antigen (PSA) were measured as a comparison.

Patients And Methods: The serum samples of 100 patients were analysed using a specific immunoassay.

Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma.

Background: The aim of the study was to investigate whether the bone turnover marker procollagen type 1 amino-terminal propeptide (P1NP) could be useful for the early detection of bone metastases in patients with renal cell carcinoma (RCC) and if chemotherapy influences P1NP concentrations in patients with bone metastases.

Patients And Methods: Serum samples of 36 patients were analyzed using a specific immunoassay. The patients were divided into three groups: 24 patients without metastatic spread, 6 patients with untreated bone metastases and 6 patients who had received sorafenib.

Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.

Background: The aim of this study was the investigation of the diagnostic value of the amino-terminal propeptide of type I collagen (P1NP) and the tumour markers, CA 15-3 and CA 125, in patients with breast and ovarian cancer.

Patients And Methods: Serum levels of P1NP, CA 15-3 and CA 125 were analyzed using specific immunoassays. Baseline serum samples of 66 patients with metastatic breast cancer and 34 patients with metastatic ovarian cancer under chemotherapy were investigated.

Peripheral percutaneous transluminal laser angioplasty in humans: in vitro investigations and clinical results with a novel laser catheter system.

Percutaneous transluminal laser angioplasty has become an accepted method of treatment of peripheral arterial occlusive disease. To minimize the risk of arterial wall perforation during laser angioplasty, a novel laser catheter system was developed. In 113 obliterated postmortem human arteries the perforation rate was 0.

[Percutaneous transluminal laser angioplasty in peripheral arterial occlusive disease--development of a new laser catheter system].

Percutaneous laser angioplasty in arterial occlusive disease has lately been performed clinically for the first time. Perforation of the arterial wall and formation of aneurysms are serious risks. Two novel laser catheters for laser angioplasty with minimized perforation risk are presented.